PHASE 2, SINGLE ARM STUDY OF CG0070 COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH NONMUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)

被引：0
|
作者：
Li, Roger [1 ]
Steinberg, Gary [2 ]
Uchio, Edward [3 ]
Lamm, Donald [4 ]
Paras, Shah [5 ]
Kamat, Ashish [6 ]
Bivalacqua, Trinity [7 ]
Packiam, Vignesh [8 ]
Chisamore, Michael [9 ]
McAdory, John [10 ]
Grandi, Paola [10 ]
Hnat, Nataliya [10 ]
Burke, James [10 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res, Tampa, FL USA
[2] NYU Langone Hlth, New York, NY USA
[3] Univ Calif Irvine, Irvine, CA USA
[4] BCG Oncol, Phoenix, AZ USA
[5] Mayo Clin, Rochester, MN USA
[6] Univ Texas MD Anderson, Houston, TX USA
[7] Univ Penn, Philadelphia, PA 19104 USA
[8] Univ Iowa, Iowa City, IA USA
[9] Merck & Co Inc, Kenilworth, NJ USA
[10] CG Oncol, Irvine, CA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0666
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
666
引用
收藏
页码：A696 / A696
页数：1
相关论文
共 50 条
  • [21] Effectiveness of the Moreau strain of Bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer.
    Chade, Daher Cezar
    Machado, Andre
    Waksman, Ricardo
    Garcia, Guilherme
    Esteves, Paulo
    Adonias, Sanarelly
    Botelho, Luis
    Cordeiro, Mauricio
    Murta, Claudio
    Ribeiro-Filho, Leopoldo
    Sarkis, Alvaro
    Bastos, Diogo Assed
    Dzik, Carlos
    Srougi, Miguel
    Nahas, William Carlos
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Pembrolizumab in patients with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study
    de Wit, R.
    Kamat, A. M.
    Bellmunt, J.
    Choueiri, T. K.
    Nam, K.
    De Santis, M.
    Dreicer, R.
    Hahn, N. M.
    Perini, R.
    Siefker-Radtke, A. O.
    Sonpavde, G.
    Witjes, J. A.
    Keefe, S.
    Bajorin, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] Utilization of Bacillus Calmette-Guerin for Nonmuscle Invasive Bladder Cancer in an Era of Bacillus Calmette-Guerin Supply Shortages
    Khanna, Abhinav
    Yerram, Nitin
    Zhu, Hui
    Kim, Simon
    Abouassaly, Robert
    UROLOGY, 2019, 124 : 120 - 125
  • [24] INTERIM RESULTS FROM A SINGLE-ARM MULTICENTER PHASE II TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
    Packiam, Vignesh T.
    Barocas, Daniel A.
    Chamie, Karim
    Davis, Ronald L., III
    Kader, A. Karim
    Lamm, Donald L.
    Curran, Dominic
    Yeung, Alex W.
    Steinberg, Gary D.
    JOURNAL OF UROLOGY, 2017, 197 (04): : E915 - E916
  • [25] KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)
    Kamat, Ashish M.
    Bellmunt, Joaquim
    Choueiri, Toni K.
    Nam, Kijoeng
    De Santis, Maria
    Dreicer, Robert
    Hahn, Noah M.
    Perini, Rodolfo F.
    Siefker-Radtke, Arlene O.
    Sonpavde, Guru
    De Wit, Ronald
    Witjes, Alfred
    Keefe, Stephen Michael
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG): Phase II KEYNOTE-057 trial
    de Wit, R.
    Kulkarni, G. S.
    Uchio, E.
    Singer, E. A.
    Krieger, L.
    Grivas, P.
    Bajorin, D.
    Seo, H. K.
    Mourey, L.
    Kamat, A.
    Nishiyama, H.
    Kapadia, E.
    Nam, K.
    Frenkl, T.
    Balar, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 304 - 304
  • [27] Bacillus Calmette-Guerin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?
    Tan, Wei Shen
    Grajales, Valentina
    Bree, Kelly
    Li, Roger
    Nogueras-Gonzalez, Graciela M.
    Navai, Neema
    Dinney, Colin
    Kamat, Ashish M.
    BJU INTERNATIONAL, 2023, 132 (04) : 384 - 386
  • [28] A phase 1 dose-escalation trial of intravesical CG0070 for superficial transitional cell carcinoma (TCC) of the bladder after bacillus Calmette-Guerin (BCG) failure
    Lamm, D
    Stephenson, J
    Tsai, H
    Nemunaitis, J
    Goldstein, M
    Arseneau, J
    Neal, K
    Aimi, J
    Yu, D
    Corman, JM
    McKiernan, JM
    Senzer, N
    Burke, JP
    JOURNAL OF UROLOGY, 2006, 175 (04): : 272 - 272
  • [29] A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma (TCC) of the Bladder after Bacillus Calmette-Guerin (BCG) Failure
    Senzer, Neil
    Nemunaitis, John
    Goldstein, Michael
    Arseneau, James
    Lamm, Don
    Stephenson, Joe
    Tsai, Harry
    Neal, Kristina
    Aimi, Junko
    Yu, D. C.
    Maslyar, Daniel
    Corman, John
    Mckiernan, James
    Burke, James
    MOLECULAR THERAPY, 2006, 13 : S22 - S22
  • [30] Pembrolizumab with favezelimab or vibostolimab for patients with High-Risk (HR) bacillus Calmette-Guerin (BCG)-unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C
    Necchi, A.
    Shore, N. D.
    Gupta, S.
    Kulkarni, G.
    Dave, H.
    Kapadia, E.
    Zhao, Q.
    Kamat, A.
    EUROPEAN UROLOGY, 2023, 83 : S748 - S748
12345